Develops antibody-based therapeutics for cancer treatment.
Jun 2026Revenue $168M/yrExpenses $208M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will Macrogenics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $168M and expenses $208M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $150M | $222M | −$72.8M |
| Dec 2024 | $150M | $261M | −$111M |
| Dec 2023 | $58.7M | $227M | −$168M |
| Dec 2022 | $152M | $273M | −$121M |
| Dec 2021 | $77.4M | $280M | −$203M |
| Dec 2020 | $105M | $236M | −$131M |
| Dec 2019 | $64.2M | $241M | −$177M |
| Dec 2018 | $60.1M | $231M | −$171M |
| Dec 2017 | $158M | $180M | −$22.1M |
| Dec 2016 | $91.9M | $152M | −$60.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.